Veloxis Pharmaceuticals recently announced the closing of its Horsholm, Denmark office and that it will be relocating to the United States.
Part of the reason Veloxis made the decision to move all of its activities to the U.S. is due to the majority of its operations being located in the country already. The move is expected to be complete by the second half of this year.
Because most of its business is already being conducted in the United States and the collaborative launch of Envarsus XR in the U.S. by its sales team, Veloxis wanted to further consolidate its activities in an effort to strengthen the company. It also sees new opportunities and avenues for business growth in the U.S.
Veloxis will remain on Nasdaq Copenhagen A/S as a Danish company. The company’s financial guidance for the 2015 fiscal year will be unaffected by the announcement to move to the United States.